US23284F1057
US23284F1057
CytomX Therapeutics, Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)
The business itself is financially solid (Financial Health 75/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±142.1% p.a.) and steep historical drawdowns.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves approx. 2.2x as much as the broader market.
Beta (Market Relation)
2.2x
Above averageVolatility (5Y p.a.)
142.1% p.a.
5-Year HorizonMax Drawdown (5Y)
-94.2%
5-Year HorizonSharpe Ratio
-0.11
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
Volatility Expansion (3Y > 5Y) High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | -26.7% |
| 3 Years | 170.3% | -91.6% | 0.14 | +26.5% |
| 5 Years | 142.1% | -94.2% | -0.11 | -12.6% |
| 10 Years | 111.4% | -98.7% | -0.17 | -16.5% |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
High market risk: Beta of 2.20 indicates above-average volatility compared to the broader market.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Elevated Short-Term Volatility: 3Y volatility (170.3%) is noticeably higher than the 5Y average (142.1%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (142.1% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -98.7% in the extended horizon.
Corporate Governance & ISS Scores
Overall Governance Risk
6 ISS Score: 6 / 10
Audit Risk
5 ISS Score: 5 / 10
Board Risk
9 ISS Score: 9 / 10
Short Ratio
11.02